Theratechnologies To Develop Tesamorelin For The Treatment Of Nash In The General Population

Phase 3 protocol to be filed in Q4 2020; trial expected to begin early 2021  Clinical study to include HIV cohort Montreal, Canada – September 10, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to …Lire la suite

Theratechnologies Announces Launch Of Trogarzo® In Germany

First commercial launch in Europe Montreal, Canada – September 10, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that Trogarzo® will be commercially available in Germany as of tomorrow through its subsidiary, Theratechnologies Europe Limited.

Theratechnologies To Present At The Canaccord Genuity 40th Annual Growth Conference On August 12, 2020

Montreal, Canada – July 30, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that Philippe Dubuc, the Senior Vice President and Chief Financial Officer of Theratechnologies, will present at the Canaccord Genuity Growth Conference on Wednesday, August 12, 2020 at 9:30 a.m. ET.

Theratechnologies Reports That Tesamorelin Improves Liver Health

Sub-analysis of MGH study helps better demonstrate how tesamorelin reduces liver fat  Positive impact of tesamorelin on oxidative phosphorylation, inflammation, tissue repair and cell division  Montreal, Canada – July 23, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce new data that further support the potential role …Lire la suite

Announcements In Conjunction With Theratechnologies Annual Meeting

Montreal, Canada – July 16, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today held its annual meeting of shareholders. As part of the meeting, shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term and elected KPMG LLP, as the Company’s auditors …Lire la suite

Theratechnologies Confirms Bioequivalence Of New Tesamorelin Formulation

sBLA expected to be filed in early 2022  Seven-day multidose vial and room temperature stability allow for the potential use of tesamorelin with a multidose pen injector  Montreal, Canada – July 7, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that it has successfully completed a …Lire la suite

Theratechnologies Announces Ibalizumab Inhibits HIV-2 In Vitro

Montreal, Canada – July 6, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that data presented at the 23rd International AIDS Conference virtual meeting, demonstrates that ibalizumab is active in vitro against group A and group B HIV-2.